The Myeloid Neoplasms Biology and Outcome Project

NCT05074316 · tracked via the Priya Life Science Germany tracker

Sponsor

University Hospital Heidelberg

Phase

Observational

Started

2020-03-10

Last updated

2025-03-25

Condition(s) studied

Myeloid Neoplasm

Study summary

The Myeloid Neoplasms Biology and Outcome Project (MyBOP) aims to establish a registry study for patients with myeloid neoplasms. It integrates clinical data, biological samples, socio-demographic information, long-term follow-up and patient reported outcomes in a structured manner for scientific purposes.

The ultimate benefits are:

1. Improvement of evidence-based clinical management of patients with myeloid neoplasms through better understanding of the course of disease and prognostic and predictive parameters
2. Direct access to new and personalized treatment approaches through recruitment into clinical studies based on the myeloid neoplasms study platform
3. Quality assurance of participating centers by evaluating and comparing clinical outcomes and side effects of the MyBOP patients with published data.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Suspected or proven diagnosis of Myeloid Neoplasms according to the WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues * Age ≥18 years * Ability to understand the nature and individual consequences of the registry * Written informed consent * Subjects who are physically or mentally capable of giving consent Exclusion Criteria: Severe neurological or psychiatric disorder interfering with the ability to give written informed consent

Primary outcome measure(s)

median overall survival (mOS) — 5 years
Time period of survival from date of diagnosis of myeloid neoplasy
overall survival (mOS) — 10 years
Time period of survival from date of diagnosis of myeloid neoplasy
event free survival (EFS) — 5 years
Time period of event free survival from date of diagnosis of myeloid neoplasy
progression free survival (PFS) — 5 years
Time period of progression survival from date of diagnosis of myeloid neoplasy

Trial sites (1)

Facility	City	Region	Status
UHHeidelberg	Heidelberg	Baden-Wurttemberg	Recruiting

More University Hospital Heidelberg trials in Germany

Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion Recruiting

Multi-professional Care Pathway and Network for the Promotion of Needs-oriented, Resident-oriented Exercise Therapy for Oncological Patients Recruiting

Clinical Performance of Long-span Fixed Partial Dentures Recruiting

Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location Active, not recruiting

Tumor-specific T Cells in Lung Cancer Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05074316 on ClinicalTrials.gov ↗ ← All trials in Germany